Version 1
: Received: 16 March 2020 / Approved: 17 March 2020 / Online: 17 March 2020 (09:17:53 CET)
How to cite:
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints2020, 2020030275. https://doi.org/10.20944/preprints202003.0275.v1
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints 2020, 2020030275. https://doi.org/10.20944/preprints202003.0275.v1
Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints2020, 2020030275. https://doi.org/10.20944/preprints202003.0275.v1
APA Style
Kearney, J. (2020). Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints. https://doi.org/10.20944/preprints202003.0275.v1
Chicago/Turabian Style
Kearney, J. 2020 "Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review" Preprints. https://doi.org/10.20944/preprints202003.0275.v1
Abstract
There is a long trail of research studies testing the in vitro and in vivo efficacy of chloroquine and its derivatives in treating and preventing infection by various coronavirus species. More recent findings have highlighted the possibility of treating patients infected with the 2019 novel coronavirus, SARS-CoV-2. This review describes the mechanism of coronavirus infection, the mechanism of action of chloroquine, and summarizes the available literature highlighting the efficacy of chloroquine as an anti-coronavirus agent. These findings should encourage the wider scientific community to conduct thorough research on the possible efficacy of chloroquine and its derivatives in treating and preventing SARS-CoV-2 infection.
Keywords
Antimalarial; Chemoprophylaxis; Chloroquine; Coronavirus; COVID-19; Global Health; Hydroxychloroquine; Public Health; SARS-CoV-2; Virus
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
22 March 2020
Commenter:
Arnold Vera MD., MSc., CDE.,FACE
The commenter has declared there is no conflict of interests.
Comment:
I would like to suggest: Chloroquine ( CQ)as a prophylaxis med for members of the health team : Administer Before the virus reach circulation from portal of entry sus as nose , mouth, oropharynge, eyes or other mucous membrane. fighting the viremia , This will prevent the Covid 19 biding cell receptor to access the cell and replicate on the other hand , especially Angiotensing receptopt T 2 receptors , Still be acting on the Homeostatic mechanism of tissue perfusion and preventing lethal shocking effect of hypotension , which is one of the main cause of death on severe respiratory infections and Covid 19 agent.Finally , Covid block and / or disrupt the hypothalamic - Pituitary- Adrenal Axis to the stress response leading to erratic immunomidulation , with low cortisol , low epinephrine ( as a result of low key enzyme COMT) then irreversible shock, hypothension,Cardiac arrhythmias , bronchospasm , hypoglycemia just to mention a few. Dosis of CQ 2-4 mg / kg body Wt X seven days periods
The commenter has declared there is no conflict of interests.
Comment:
Several trials are beginning in the United States testing the post-exposure prophylaxis use of hydroxychloroquine. One trial at the University of Minnesota (https://med.umn.edu/news-events/covid-19-clinical-trial-launches-university-minnesota) and another at the University of Washington (https://newsroom.uw.edu/news/does-antimalarial-drug-prevent-covid-19-study-seeks-answers.
Commenter:
The commenter has declared there is no conflict of interests.
Commenter: Arnold Vera MD., MSc., CDE.,FACE
The commenter has declared there is no conflict of interests.
Commenter:
The commenter has declared there is no conflict of interests.
Commenter: John Kearney
The commenter has declared there is no conflict of interests.